Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | WEE1 | P30291 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12854521 | 0.94 | EGFR (0.44) | BRD4PDGFRBPDGFRAWEE1EGFR | |
| SCHEMBL12854507 | 0.92 | BRD4 (0.48) | BRD4PDGFRBPDGFRAWEE1EGFR | |
| SCHEMBL12854522 | 0.91 | BRD4 (0.52) | BRD4CCNKCCNA2CDK2CCND3 | |
| SCHEMBL12854464 | 0.88 | WEE1 (0.49) | BRD4PDGFRBPDGFRAWEE1EGFR | |
| SCHEMBL12854495 | 0.86 | WEE1 (0.47) | BRD4PDGFRBPDGFRAWEE1EGFR | |
| SCHEMBL12854502 | 0.85 | FLT3 (0.49) | BRD4PDGFRBPDGFRAWEE1EGFR | |
| SCHEMBL12854451 | 0.85 | BRD4 (0.52) | BRD4PDGFRBPDGFRAWEE1EGFR | |
| SCHEMBL12854496 | 0.85 | WEE1 (0.48) | BRD4WEE1EGFRTNK2 | |
| SCHEMBL12854504 | 0.84 | WEE1 (0.47) | BRD4WEE1EGFRTNK2 | |
| SCHEMBL12854514 | 0.83 | CTSC (0.46) | BRD4EGFRCCNKCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040527-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | BRD4 758/4885PDGFRB 1086/4885PDGFRA 1064/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | BRD4 789/4885PDGFRB 1315/4885PDGFRA 1259/4885 |
| US-20130309228-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | BRD4 758/4885PDGFRB 1086/4885PDGFRA 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.